Scott Lassman co-authored the article, "Clinical Trial Transparency: a Reassessment of Industry Compliance With Clinical Trial Registration and Reporting Requirements in the United States," BMJ Open, Volume 7, Issue 9 (2017). The article analyzes compliance with clinical trial disclosure laws in the U.S.
Scott Lassman evaluates criticism of the FDA citizen petition process in his article, "Criticism of FDA Citizen Petitions is Often Misguided," Law360, November 20, 2017.
Scott Lassman spoke on the FDA approval process for drugs and biologics at ACI's FDA Boot Camp in Boston.
Chambers USA: America’s Leading Lawyers for Business has recognized Scott Lassman for his work in Pharmaceutical/Medical Products Regulatory law.
The Chambers rankings are determined by independent research into a range of qualities and evidence of an attorney's work.
Scott Lassman spoke on the FDA approval process for drugs and biologics at ACI's FDA Boot Camp in New York, NY.
Scott Lassman spoke on FDA developments at the 2016 All Hands Meeting for the Life Sciences track in Santa Clara, CA.
Scott Lassman was a speaker on the panel "The New Drug Approval Process: Basic Concepts" at FDLI’s Introduction to Drug Law Course.